fepblue glp 1 coverage What FEHB changes mean for your 2026 health FEP Blue update to PA

News provided by Novo Nordisk May 07, 2026, 07:00 ET Eligible Medicare patients living with obesity will have access to Wegovy (semaglutide) injection and pill for a $50 monthly copay Wegovy offers adults living with obesity significant weight loss, along with diet and exercise, and is FDA-approved to lower the risk of major CV events such as death, heart attack, or stroke in adults living with obesity with known heart disease, a claim only Wegovy can make Novo Nordisk's participation in the Medicare GLP-1 Bridge expands patient access to authentic, FDA-approved Wegovy PLAINSBORO, N.J., May 7, 2026 /PRNewswire/ -- The Medicare GLP-1 Bridge will provide eligible Medicare beneficiaries living with obesity access to Wegovy (semaglutide) injection and tablets for a $50 monthly copay , beginning July 1, 2026, per yesterday's announcement from the Centers for Medicare & Medicaid Services (CMS)

(link to article in the comments) #GLP1s #WeightLossDrugs #EmployeeBenefits To view or add a comment, sign in 27% of employers say GLP-1 weight-loss drugs made up more than 15% of their total annual claims in 2024

Individuals within the age range of 4154 years old, males, or had taken one of 36 drugs, including Tigecycline, were at higher risk for developing drug-related AP

~ AlphaMD Youve heard trust your gut but did you know your gut might also have a say in your testosterone levels

Not mostly strict. Strict

Eat citrus fruits, green leaves, nuts, and lean protein